VCYT
NASD Veracyte, Inc.$45.81 ↑ +0.00 (+0.00%) Trading Up from the previous close of $45.81, $0.28 below the day’s high of $46.09
- YTD change
- +8.81%
- vs 20-day SMA
- +6.43%
- vs 200-day SMA
- +7.79%
Price ranges
Price & Performance
+13.49 (+41.74%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 46.8% away from all-time highs of $86.03
- VCYT is up 9% since the beginning of the year
- VCYT is up 29% over the past 12 months
- VCYT is up 2% over the past 1 month
- 11% of all VCYT investors are betting against VCYT
VCYT reads neutral: price sits above both the 20- and 200-day averages, the 12-month move is +27.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.31
- Last 5 days
- -5.62%
- vs 8-day SMA
- +1.04%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.